Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

6.265 +0.045 (+0.72%)

Streaming Delayed Price Updated: 12:36 PM EST, Feb 11, 2026 Add to My Watchlist

Price and Volume

Volume	11,186
Open	6.270
Bid (Size)	6.240 (100)
Ask (Size)	6.290 (1,000)
Prev. Close	6.220
Today's Range	6.180 - 6.270
52wk Range	3.533 - 6.570
Shares Outstanding	72,407,215
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis

January 09, 2026

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Life Sciences Reports Third Quarter 2025 Financial Results

November 12, 2025

From Kezar Life Sciences, Inc.

Via Business Wire

Performance

YTD	-0.4%	-0.4%
1 Month	+2.0%	+2.0%
3 Month	+1.4%	+1.4%
6 Month	+60.6%	+60.6%
1 Year	+3.0%	+3.0%

More News

Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025

November 07, 2025

From Kezar Life Sciences, Inc.

Via Business Wire

Looking Into Kezar Life Sciences's Recent Short Interest ↗

October 29, 2024

Via Benzinga

Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans ↗

October 17, 2025

Via Benzinga

Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive ↗

October 17, 2025

Via Stocktwits

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 17, 2025

Via Benzinga

This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

October 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 17, 2025

Via Benzinga

Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket ↗

October 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 16, 2025

Via Benzinga

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

October 16, 2025

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

August 28, 2025

From Kezar Life Sciences

Via Business Wire

Kezar Narrows Loss 37 Percent in Q2 ↗

August 13, 2025

Via The Motley Fool

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

August 13, 2025

From Kezar Life Sciences, Inc.

Via Business Wire

FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study ↗

July 16, 2025

Via Benzinga

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

July 15, 2025

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

May 28, 2025

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate ↗

March 25, 2025

Via Benzinga

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

March 25, 2025

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

March 24, 2025

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

February 18, 2025

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

November 12, 2024

From Kezar Life Sciences, Inc.

Via Business Wire

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

November 05, 2024

From Glancy Prongay & Murray LLP

Via Business Wire

Frequently Asked Questions

Is Kezar Life Sciences, Inc. - Common Stock publicly traded?

Yes, Kezar Life Sciences, Inc. - Common Stock is publicly traded.

What exchange does Kezar Life Sciences, Inc. - Common Stock trade on?

Kezar Life Sciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Kezar Life Sciences, Inc. - Common Stock?

The ticker symbol for Kezar Life Sciences, Inc. - Common Stock is KZR on the Nasdaq Stock Market

What is the current price of Kezar Life Sciences, Inc. - Common Stock?

The current price of Kezar Life Sciences, Inc. - Common Stock is 6.265

When was Kezar Life Sciences, Inc. - Common Stock last traded?

The last trade of Kezar Life Sciences, Inc. - Common Stock was at 02/11/26 12:36 PM ET

What is the market capitalization of Kezar Life Sciences, Inc. - Common Stock?

The market capitalization of Kezar Life Sciences, Inc. - Common Stock is 453.63M

How many shares of Kezar Life Sciences, Inc. - Common Stock are outstanding?

Kezar Life Sciences, Inc. - Common Stock has 454M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.